Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0GMBZN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
T-VCR 6b
|
|||||
| Synonyms |
T-VCR 6b
Click to Show/Hide
|
|||||
| Organization |
Institut de Recherche de l'Ecole de Biotechnologie de Strasbourg.; Centre National de la Recherche Scientifique/Université de Strasbourg.
|
|||||
| Drug Status |
Investigative
|
|||||
| Drug-to-Antibody Ratio |
7.8
|
|||||
| Structure |
|
|||||
| Antibody Name |
Trastuzumab
|
Antibody Info | ||||
| Antigen Name |
Receptor tyrosine-protein kinase erbB-2 (ERBB2)
|
Antigen Info | ||||
| Payload Name |
Vincristine (VCR)
|
Payload Info | ||||
| Linker Name |
Mc-Val-Cit-PABC
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | 0.02۪.01 nM | High HER2 expression (HER2 +++) | ||
| Method Description |
Cells were seeded in 96-well plates at a density of 2000 cells/well for MDA-MB-231 cells and 5 000 cells/well for all the other cell lines and allowed to grow under normal oxygen conditions (20% O2). Cells were treated with the appropriate compound 24 h after plating and maintained at 37 °C under a humidified 5% CO2 and 20% O2 atmosphere. Cell viability was measured 72 or 120 h later with the WST-1 cell proliferation assay (Takara) according to the manufacturer's instructions. To represent the relative cell proliferation rate, results were normalized against the untreated condition.
Click to Show/Hide
|
||||
| In Vitro Model | Breast adenocarcinoma | SK-BR-3 cells | CVCL_0033 | ||
